cholesterol efflux promotes pathogenic HSPC expansion and proliferation leading to uncontrolled myelopoiesis. [5] [6] [7] [8] For instance, in the ApoE −/− mouse model of atherosclerosis, the progressive HSPC expansion that drives myelopoiesis 6 contributed to provide the inflamed atherosclerotic lesions with neutrophils and monocytes. [9] [10] [11] Although recent research has focused on elucidating the roles of cytokines and the microenvironment in the proliferation, mobilization, and commitment of HSPCs in preclinical model of atherosclerosis, 1,2 the cellular metabolic pathways that regulate these processes remain unknown.
Lessons from various mutant mice displaying a wide range of bioenergetic defects in vivo have pointed to a central role for the mitochondrial energy metabolism in HSC stemness. [12] [13] [14] [15] [16] [17] Mounting evidence also suggests that HSC quiescence requires a hypoxic environment 18, 19 to maintain glycolysis-biased metabolic activity instead of mitochondrial oxidative phosphorylation. 20, 21 By limiting mitochondrial respiration and ATP production, this could indeed prevent HSCs from producing reactive oxygen species to avoid their differentiation and exhaustion. [22] [23] [24] In contrast, funneling glucose to the mitochondria for Krebs cycle utilization is required when the HSCs become proliferative or undergo differentiation, most likely because of the high energy demand of these cellular processes. 21, 25 More recently, Oburoglu et al 26 have also reported that glucose utilization can dictate the myeloid lineage commitment in human HSCs. Intriguingly, increased hematopoietic metabolic activity can be visualized by noninvasive positron emission and computed tomographic imaging with 18 F-fluorodeoxyglucose, a glucose analog, not only in inflamed atherosclerotic plaques [27] [28] [29] [30] but also in the spleen of patients with cardiovascular diseases, 31, 32 reflecting most likely an extramedullary hematopoiesis. 33 However, the relevance of these observations as well as the underlying mechanisms are not fully understood.
In an attempt to better understand the relation between the enhanced hematopoietic glycolytic activity, HSPC proliferation, myelopoiesis, and the development of atherosclerotic lesions, we first showed that an enhanced hematopoietic glycolytic activity in the aortic arch, the BM, and the spleen of ApoE −/− BM-transplanted mice was associated with an enhanced glucose transporter type 1 (Glut1) expression in
ApoE
−/− HSPCs. Mechanistic studies showed that the upregulation of Glut1 in ApoE −/− HSPCs was not because of an alteration of the oxygenation status of the BM niche but rather was dependent on Ras signaling downstream of the granulocytemacrophage colony-stimulating factor (GM-CSF)/interleukin-3 (IL-3) receptor driving glycolytic substrate utilization by mitochondria. Finally, we performed BM transplantation from mice with single or combined deficiencies of ApoE or the glucose transporter Glut1 into ApoE −/− mice. Consistent with our hypothesis, ApoE −/− mice that had received ApoE −/− Glut +/− BM showed reduced HSPC proliferation and expansion, myelopoiesis, and atherogenesis compared with mice that had received ApoE −/− BM. Thus, we proposed a causal relation between the enhanced hematopoietic glycolytic activity in ApoE −/− mice and their myelopoiesis through regulation of HSPC expansion and fate, offering novel therapeutic perspectives.
Methods
Materials and additional methods are available in Online Data Supplement.
Mice and Treatments

Glut1
+/− mice (kindly provided by Dr De Vivo, Columbia University) have been crossed to C57BL/6J for >12 generations within our colony. ) mice expressing Ly5.1 cyclodextrin (CD45.2) were crossed to wild-type (WT) mice expressing Ly5.2 (CD45.1) to generate ApoE −/− mice expressing Ly5.2 (CD45.1). For each experiment, littermate controls were generated. For the neutralizing antibody experiment, WT and ApoE −/− mice were intravenously injected with IgG control or IL-3Rβ AF549 antibody (R&D systems). Animal protocols were approved by the Institutional Animal Care and Use Committee of the French Ministry of Higher Education and Research and the Mediterranean Center of Molecular Medicine (Inserm U1065) and the were undertaken in accordance with the European Guidelines for Care and Use of Experimental Animals. Animals had free access to food and water and were housed in a controlled environment with a 12-hour lightdark cycle and constant temperature (22°C).
BM Transplantation
BM transplantation was performed as previously described, 5 using BM from 12-to 14-week-old WT, Glut1 6 ). Briefly, studies were conducted in 12-week-old female ApoE −/− mice fed with a Western type diet (TD88137) from Harlan Teklad (Madison, WI) for 12 weeks. Mice were allowed to recover for 5 weeks after irradiation and BM transplantation before diet studies were initiated. Body weight was recorded at indicated time points. Mice were euthanized in accordance with the American Veterinary Association Panel of Euthanasia. Spleen weights were determined at the time of euthanasia.
Flow Cytometry Analysis
Blood Leukocytes
For identification of peripheral blood leukocytes, 100 μL of blood was collected into EDTA tubes before red blood cell lysis (BD Pharm Lyse; BD Biosciences), filtration, and staining for 30 minutes on ice. Cells were stained with a cocktail of antibodies against CD45, Ly6C/G, CD115, B220, TCR-β, and CD8 as previously described. 5 Briefly, monocytes were identified as CD45 For DNA content analysis, HSPC-stained BM cells were fixed in 1% paraformaldehyde in PBS, washed, and stained with 4',6-diamidino-2-phenylindole (5 μg/mL; Molecular Probes). Cell surface expression of Glut1 was quantified using Glut1 FAB1418 antibody from R&D systems or Glut1 receptor binding domain ligand (Metafora Biosystems). To assess the uptake of 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D-glucose (2-NBDG), prestained cells were incubated with 10 μmol/L 2-NBDG (invitrogen) for 30 minutes as previously described. 34 The mitochondrial membrane potential (MMP) and reactive oxygen species production were analyzed with 25 nmol/L fluorescent tetramethylrhodamine ethyl ester (AnaSpec) and 5 μm CM-H2DCFDA stainings for 30 minutes on prestained BM cells. In addition, autophagy was monitored in live cells using Cyto-ID autophagy detection kit (Enzo Life Sciences, Lyon, France) according to manufacturer instructions. Viable cells, gated by light scatter or exclusion of CD45 − cells, were analyzed on a 4-laser BD Canto cell analyzer or sorted on a BD FACSAria Cell Sorter both running with DiVa software (BD Biosciences). Data were analyzed using FlowJo software (Tree Star Inc).
Statistical Analysis
Data are shown as mean±SEM. Statistical significance was performed using Prism t test or ANOVA according to the data set. Results were considered as statistically significant when P<0.05. Figure 1A) . A ≈3.5-fold increase in 2-deoxy [
Results
Enhanced Glucose Uptake in Atheromatous Plaques
14 C] glucose uptake was also consistently observed in colony forming unit assays with the multipotential progenitors and GMP from the ApoE −/− mice ( Figure 1B ). The oxygen consumption was 1. Figure 1C ). The higher oxygen consumption seen in ApoE −/− cells was most likely maintained by mitochondrial oxygen consumption because treatment with oligomycin, which inhibits mitochondrial ATP synthase, clearly suppressed their respiration ( Figure 1D ). Quantification of the citric acid metabolites by liquid chromatography-mass spectometry showed higher citrate, fumarate, and malate but not succinate in ApoE −/− leukocytes ( Figure 1E ). This was associated with a 1.7-fold increase in succinate dehydrogenase activity in ApoE −/− leukocytes (WT, 13.7±1.9 versus ApoE −/− , 24.2±4.1 ∆OD/min per mg protein, respectively). Consistent with these findings, a ≈1.3-fold increase in the MMP was observed in ApoE −/− Lineage marker-positive (Lin + ) and Lin − BM cells by flow cytometry using a fluorescent tetramethylrhodamine ethyl ester dye ( Figure 1F ). An analysis of the different populations within the HSPCs showed that the mitochondrial potential of the CD34 − LT-HSCs and CD34 + HSPCs 35, 36 was increased to the same extent as the Lin − BM cells in the ApoE −/− mice ( Figure 1F ). This was associated with an increase in reactive oxygen species staining in these cells (data not shown). To test whether this phenotype was caused by modulation of the glycolytic pathway in HSPCs, we next used the fluorescent D-glucose analog, 2-NBDG, as a tool to examine the glucose uptake in these cells. 34 The NBDG staining was increased by ≈1.5-fold in the ApoE −/− Lin + and Lin − BM cells and CD34 + HSPCs, but not in the more primitive fractions of the CD34 − LT-HSCs ( Figure 1G ). We next assessed the cell surface expression of the glucose transporter 1 (Glut1) in these cells by flow cytometry. A ≈1.25-fold increase in the Glut1 cell surface expression was observed in the ApoE −/− Lin + and Lin − BM cells and CD34 + HSPCs, but not CD34
− LT-HSCs ( Figure 1H ). This was similar to the NBDG pattern. Together, these observations suggest that the enhanced Glut1 expression and associated glycolytic activity in organs from ApoE −/− BM-transplanted mice could reflect the metabolic state not only of leukocytes but also of HSPCs. Figure IC) . Thus, to directly test the contribution of HIF-1α in the regulation of Glut1-dependent glucose metabolism in ApoE −/− HSPC in vivo, we next generated an inducible, hematopoietic-specific HIF-1α knockout (Mx1-cre HIF1α fl/ fl ) on a WT or ApoE −/− background. The BM from these mice was transplanted into irradiated ApoE −/− mice and after a recovery period, the recipients were fed with a high-fat diet for 12 weeks to exacerbate their HSPC expansion (Figure 2A ). 6 HIF-1α was deleted from hematopoietic cells before the start of the diet by sequential polyl:polylC injections, which efficiently excised the HIF-1α gene from the BM cells ( Figure   2B and 2C). Lactate dehydrogenase mRNA expression was also significantly reduced in the BM of these mice, but Glut1 was only marginally regulated ( Figure 2C ). Also, HIF-1α deficiency did not alter the cell surface expression of Glut1 in CD34 + HSPCs and CD34 − LT-HSCs ( Figure 2D ) or the frequency of these cells ( Figure 2E ). Furthermore, quantification of the blood myeloid cells in these mice revealed that HIF-1α deficiency further increased the neutrophil, monocyte, and eosinophil counts in these mice ( Figure 2F ). Together, these findings suggest that HIF-1α does not mediate the upregulation of Glut1 in ApoE −/− HSPC or their expansion and minimally contributed to myelopoiesis under hypercholesterolemic conditions. − and CD34 + HSPCs. E, Quantification of the CD34 − or CD34 + HSPCs by flow cytometry was expressed as the percentage of total BM. F, Peripheral blood neutrophils, monocytes, and eosinophils were also quantified in these mice at the end of the study period. Figure IIA) . These responses were not observed for the HIF-1α or lactate dehydrogenase mRNAs (Online Figure IIA) . Flow cytometry analysis confirmed an increase in Glut1 cell surface expression in ApoE −/− HSPCs on IL-3 and GM-CSF stimulation compared with WT HSPCs (Online Figure IIB) . These effects were abrogated by blocking the IL-3Rβ signaling pathway and downstream Ras activation with a farnesyl transferase inhibitor, but not by the Jak2 inhibitor, AG490, or the AMP-activated protein kinase activator, metformin (Online Figure IIB) . Removing plasma membrane cholesterol with cyclodextrin also prevented the enhanced Glut1 expression in ApoE −/− HSPCs confirming the central role of cholesterol in this regulation (Online Figure  IIB) , To directly test the relevance of these observations in vivo, an IL-3Rβ blocking antibody was next injected into the WT and ApoE −/− mice. Consistent with earlier work, 40 we first showed that this antibody efficiently reduced myelopoiesis in the ApoE −/− mice and had no effect in WT mice during the 24-hour period ( Figure 3A ). An analysis of the genes in the glycolytic pathway in the BM cells at the end of the study period revealed no significant changes in the HIF-1α or lactate dehydrogenase mRNAs, but the Glut1 mRNA was downregulated after treatment with the IL-3Rβ blocking antibody in the ApoE −/− BM (Online Figure IIC) . Quantification of the HSPCs in the BM of these mice by flow cytometry also revealed reduced numbers of CD34 + , but not CD34 − HSPCs, in the ApoE −/− mice, but not in the WT mice ( Figure 3B ), which correlated with reduced cycling of these cells ( Figure 3C ). This was associated with the reduced cell surface expression of Glut1 in the ApoE −/− CD34 + HSPCs ( Figure 3D ). These results revealed that the metabolic requirements for proliferation and expansion of the ApoE −/− HSPCs are associated with the IL-3/Glut1 axis and not the HIF-1α/Glut1 axis in vivo.
HIF-1α Is
Inhibition of Mitochondrial Glycolytic Substrate Utilization Prevents ApoE −/− HSPC Proliferation and Myelomonocytic Fate In Vitro
To determine the contribution of mitochondrial oxidative phosphorylation on ApoE −/− HSPC proliferation and lineage specification on IL-3 and GM-CSF treatment, we next artificially suppressed various enzymes that are intricately involved in the regulation of the tricarboxylic acid cycle using pharmacological inhibitors ( Figure 4A ). We first validated our in vitro BM culture assay by showing that inhibition of the IL-3Rβ signaling pathway (IL-3Rβ blocking antibody), inhibition of Ras signaling (farnesyl transferase inhibitor FTI-277), and plasma membrane cholesterol depletion with cyclodextrin prevented ApoE −/− HSPC expansion ( Figure 4B ) and the generation of CD11b Figure 4C ). In contrast, inhibition of lactate dehydrogenase and acetyl-CoA carboxylase using oxamate and Tofa, respectively, or activation of AMP-activated protein kinase with metformin did not alter ApoE −/− HSPC expansion ( Figure 4B ) or their myeloid fate ( Figure 4C) . Surprisingly, inhibition of mitochondrial respiratory chain complex I with rotenone was also not sufficient to dampen ApoE −/− HSPC expansion and myeloid commitment ( Figure 4B and 4C) . Given the enhanced succinate dehydrogenase activity observed in ApoE −/− BM cells, we next evaluated the contribution of the mitochondrial complex II. Inhibition of succinate dehydrogenase with 3-nitropropionic acid specifically prevented the myeloid fate of ApoE −/− HSPCs, but not their expansion ( Figure  4B and 4C). We next assessed whether inhibition of the conversion of pyruvate for entry to the tricarboxylic acid cycle with a pyruvate dehydrogenase inhibitor (CPI-613) and a pyruvate carboxylase inhibitor (chlorothricin) could alter the expansion and myeloid fate of ApoE −/− HSPCs. Although ApoE −/− HSPC expansion required both inhibition of pyruvate dehydrogenase and pyruvate carboxylase ( Figure 4B ), their myeloid fate was actually suppressed by inhibiting either pyruvate dehydrogenase or pyruvate carboxylase ( Figure 4C ). This revealed that the conversion of both succinate and pyruvate into the tricarboxylic acid cycle are central metabolic checkpoints for ApoE −/− HSPC myeloid lineage specification and to some extent ApoE −/− HSPC expansion. Interestingly, the conversion of succinate to fumarate and pyruvate to oxaloacetate converge to the malate-aspartate shuttle, known to maximize the number of ATP molecules produced in glycolysis. 41 To address the contribution of this pathway, we suppressed transaminases including glutamate oxaloacetate transaminases using aminooxyacetic acid. This molecule has been shown to prevent the mitochondria from using glycolytic substrates by inhibiting the malate-aspartate shuttle. 42 Remarkably, treatment with aminooxyacetic acid not only prevented ApoE −/− HSPC expansion ( Figure 4B ) but also their myeloid fate on IL-3 and GM-CSF treatment ( Figure 4C ). These data collectively suggest that mitochondrial metabolic reprogramming of ApoE −/− HSPCs is required for their expansion and commitment to the myeloid lineage.
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Glut1 Mediates the IL-3Rβ-Dependent ApoE
−/−
HSPC Proliferation and Myelomonocytic Fate In Vitro
To bolster our observations, we next generated single or combined knockout of ApoE (ApoE Figure 5E and 5F). This mirrored the reactive oxygen species production and MMP assessed by flow cytometry in HSPCs at the end of the culture period ( Figure 5G and 5H) . Mechanistically, we next tested whether Glut1 may mediate the effect of IL-3 on autophagy 43 because autophagy has recently emerged to regulate HSPC maintenance and a bias toward myelopoiesis. 44, 45 Western blot analysis of microtubule-associated protein light chain 3-II protein levels, an hallmark of autophagy, revealed that Glut1 deficiency prevented the decrease of microtubule-associated protein light chain 3-II expression in WT and ApoE −/− BM cells under basal and IL-3-stimulated conditions (Online Figure IIIA) . To analyze the autophagic flux of HSPCs, we next used the Cyto-ID probe allowing analysis by multicolor flow cytometry. Remarkably, Glut1 deficiency prevented the reduced Cyto-ID staining induced by IL-3 in HSPCs isolated from WT Lin − cultures and restored the autophagic flux of ApoE −/− HSPCs to the level of control cells (Online Figure IIIB and IIIC). These data identify that Glut1 is a key metabolic sensor mediating the growth-regulatory effects of IL-3 through autophagy-dependent modulation of HSPC expansion and myeloid commitment in vitro.
Reduced Glycolytic Activity in Mice With Hematopoietic Glut1 Deficiency Prevents ApoE
−/−
HSPC Expansion and Proliferation
To directly test the in vivo physiological relevance of Glut1 on ApoE −/− HSPCs, we transplanted the BM of single or combined knockout of ApoE (ApoE −/− ) and Glut1 (Glut1
After a recovery period, the recipients were fed with a high-fat diet for 12 weeks using the similar experimental design described earlier ( Figure 6A ). At the end of the study period, we confirmed the efficiency of the transplantation procedure by showing a ≈1.3-fold and 1.5-fold decrease in Glut1 expression in mice receiving Glut1 +/− or ApoE
+/− BM, respectively, using Glut1 antibody and Glut1 receptor-binding domain ligand by flow cyotmetry ( Figure 6B ). An analysis of the different populations within the HSPCs of these mice was next performed (Online Figure IV) . As shown in Figure 1F , low Glut1 cell surface expression was observed in the CD34 − LT-HSCs ( Figure 6C ; Online Figure IVD ), which were also characterized by CD150 + and Flt3 − markers (Online Figure IVA-IVC) . 35, 36 Figure 6C ). Consistent with these findings, the Glut1 cell surface expression was decreased by a ≈1. 
Glut1
+/− BM could be associated with a defective myeloid fate specification. The CMP, GMP, and megakaryocyte-erythrocyte progenitor populations were analyzed by flow cytometry (Online Figure IVG) and were not significantly reduced in the mice receiving Glut1 +/− BM, despite a trend toward CMPs ( Figure 6H) . Nevertheless, the CMP numbers were significantly decreased by >1.2-fold in mice receiving ApoE
+/− BM compared with controls receiving ApoE −/− BM ( Figure 6H ). We noticed that the splenomegaly in the mice receiving the ApoE −/− BM was rescued by Glut1 deficiency (Online Table I ), and the spleen represents an important reservoir of myeloid cells through extramedullary hematopoiesis in ApoE −/− mice. 6, 33 Therefore, the hematopoietic progenitors were next quantified in this organ. Similar to the BM, we observed a 1.6-fold decrease in the frequency of splenic CMPs in mice receiving ApoE these findings, the platelet and red blood cell counts, mean platelet volume, and hematocrit were unchanged in these mice (Online Table I ). Peripheral T-and B-cell numbers were also not affected in these mice (Online Figure VA and VB) . In contrast, the blood counts indicated that the leukocytosis, monocytosis, neutrophilia, and eosinophilia of mice receiving ApoE −/− BM in response to feeding a high-fat diet were rescued by Glut1 deficiency (Figure 6J-6M ). These data indicate that Glut1-dependent glucose utilization is required at the early stage of ApoE −/− HSPC commitment to the myeloid lineage.
Glut1 Acts in a Cell-Autonomous Fashion to Regulate ApoE −/− HSPC Proliferation and Myelopoiesis
To test whether this phenotype was caused by cell autonomous effects of Glut1 within the myeloid-biased HSPCs or involved in a cell extrinsic effect, we performed a competitive BM transplantation experiment with equally mixed BM cells from CD45. 
Glut1
+/ HSPCs ( Figure 7A ). These findings mirrored the reduced S/G2M fraction in the CD45. 
Glut1 Deficiency Prevents the Progression of Atherosclerosis in ApoE −/− BM-Transplanted Mice
We next explored the in vivo relevance of reducing ApoE −/− HSPC proliferation and myelopoiesis through Glut1 
Glut1
+/− BM showed a ≈1.4-fold decrease in the development of atherosclerosis in their proximal aortas ( Figure 8A ). Immunohistochemical staining of the aortic root plaques revealed that this phenotype was associated with a massive decrease in the F4/80 + macrophages in the ApoE Figure 8C ) and the spleen ( Figure 8D ), respectively, compared with controls. We next analyzed Ly6C hi monocyte recruitment into atherosclerotic plaques using fluorescent-labeled latex beads, as previously described. 10 Figure 8E reveals that 2 days after monocyte labeling, there was a ≈1. 8 
+/− BM compared with controls 2 days after labeling (data not shown) reflecting their reduced monocytosis ( Figure 6K ). Thus, we showed that Glut1 connects the enhanced glucose uptake in atheromatous plaques of ApoE −/− mice [27] [28] [29] [30] with their myelopoiesis through regulation of HSPC maintenance and myelomonocytic fate.
Discussion
Previous studies have shown that inflamed atherosclerotic plaques can be visualized by noninvasive positron emission and computed tomographic imaging with 18 F-fluorodeoxyglucose, a glucose analog, which correlates with macrophage accumulation and inflammation. [27] [28] [29] [30] However, a recent study has called into question the relevance of these observations because macrophage-specific overexpression of Glut1 did not aggravate atherosclerosis in mice compared with Glut1 sufficient controls, 46 reflecting the need for a better understanding of the underlying mechanisms. Our study provides direct evidence that Glut1 connects the enhanced glucose uptake in atheromatous plaques of ApoE −/− mice with their myelopoiesis through Glut1-dependent regulation of HSPC maintenance and myelomonocytic fate. Recent studies have suggested that HSPC expansion and the associated myelopoiesis could underlie the hypercholesterolemia-induced atherosclerosis in mice. 1, 2 However, the rate of ATP generation required for cell proliferation and differentiation cannot be directly explained by cholesterol and requires alternative sources of energy. 47 Our observations indicate that the leukocytes and HSPCs from hypercholesterolemic ApoE −/− mice exhibited an increased Glut1-dependent glucose uptake that was associated with increased mitochondrial potential, suggesting that the influx of glycolytic metabolites in these cells fuel the mitochondria for oxidative phosphorylation and ATP generation. 21 The low expression of Glut1 in CD34 − LTHSCs compared with other CD34 + HSPCs was first counterintuitive because we initially speculated that the presence of the LT-HSCs in the hypoxic BM niche could favor the expression of Glut1 by HIF-1α. 37 However, increasing glucose metabolism through translocation of Glut1 to the cell surface is thought to be crucial for the active cells and cell cycle entry rather than quiescence.
48, 49 During aerobic respiration, the ATP yield is linked to NAD + -dependent oxidative steps, including oxidative decarboxylation of pyruvate, that requires metabolic shuttle systems to convey reducing equivalents from cytosol to mitochondria. 41 Our findings indicate that both the oxidative decarboxylation of pyruvate and the transamination reactions of the malate-aspartate shuttle were essential for HSPC expansion and commitment to the myeloid lineage. Thus, it is probably not surprising that we did not observe an accumulation of succinate in ApoE −/− BM cultures because of higher succinate dehydrogenase activity favoring fumarate and malate production. The absence of succinate accumulation in ApoE −/− BM cells could also contribute to the lack of HIF-1α activation in these cells. 50 Consistent with these observations, we did not observe modulation of the oxygenation status of ApoE −/− LTHSCs in chronic hypercholesterolemia, and HIF-1α deficiency in WT or ApoE −/− hematopoietic cells did not alter Glut1 expression or the HSPC frequency. In fact, HIF-1α deficiency in hematopoietic cells rather led to increased myeloid expansion, which could contribute to the role of hypoxia in the development of atherosclerosis. 51 In contrast and consistent with the alternative regulation of Glut1 by growth hormone-dependent activation of Ras or Src, 38, 39 the enhanced Glut1 expression in proliferating ApoE −/− HSPCs was prevented by IL-3Rβ blockade. This metabolic regulation was critical for the expansion of ApoE −/− HSPCs and the associated IL-3-dependent downregulation of autophagy, 43 which is most likely required to limit intracellular lysosomal degradation and fulfill the high-energy demand of these cells for proliferation.
Recently, increased splenic activity in patients with cardiovascular diseases has been demonstrated by noninvasive positron emission and computed tomographic imaging with 18 F-fluorodeoxyglucose, 31, 32 which could reflect the metabolic activity of extramedullary hematopoiesis required to generate monocytes that infiltrate atherosclerotic plaques. 33 However, these observations do not prove causality. Intriguingly, inhibition of glucose uptake with a 2-deoxyglucose (2-DG) analog has recently been shown to inhibit myelopoiesis in human HSCs, 26 but the relevance to atherosclerosis has not been tested. The present study clearly establishes that the increased Glut1-dependent glucose utilization in the 
Flt3
− MMP3 exhibited a myeloid-biased multipotential progenitor phenotype, offering an alternative explanation to the role of Glut1 in favoring myelopoiesis that is independent of a change in other lineage commitments. Together, these findings reveal that the mechanism by which defective ApoE-dependent cholesterol efflux pathways skew HSCs toward myelopoiesis 5,6 relies on the regulation of Glut1-dependent glucose uptake by the IL-3Rβ signaling pathway.
The metabolic phenotype of ApoE −/− HSPCs outlined here could be relevant to the adaptability of HSPCs to cholesterol overload and may indicate that the glycolytic phenotype of HSPCs is not merely a product of their hypoxic environment. Thus, the existence of different molecular mechanisms underlying the different glycolytic phenotypes in HSPCs may suggest strategies for specifically modulating the pool of HSPCs that are committed to the myeloid lineage under stressed conditions, such as in myeloproliferative disorders, 36 sepsis, 53 myocardium infarction, 54 or chronic atherosclerosis, as shown in the present study. Inhibition of glucose uptake by a Glut1 inhibitor that does not cross the blood-brain barrier could ultimately provide a novel therapeutic approach to prevent myelopoiesis-driven diseases, such as atherosclerosis.
What Is Known?
• Increased hematopoietic metabolic activity can be visualized by noninvasive positron emission and computed tomographic imaging with 18 F-fluorodeoxyglucose, a glucose analog, not only in inflamed atherosclerotic plaques but also in the spleen of patients with cardiovascular diseases.
• Increased glucose metabolism is thought to be crucial for cellular proliferation, but direct evidence of its role in hematopoiesis is lacking.
What New Information Does This Article Contribute?
• The induction of Glut1 in ApoE −/− hematopoietic stem and progenitor cells is the consequence of the growth-regulatory effects of IL-3 and granulocyte-macrophage colony-stimulating factor driving glycolytic substrate utilization by mitochondria.
• Deletion of the Glut1 gene limits the enhanced glycolytic and mitochondrial activity of ApoE −/− hematopoietic stem and progenitor cells, attenuating the high-energy demand of these cells for proliferation and expansion and preventing the development of atherosclerosis.
• These findings suggest the presence of proatherogenic cross-talk between nutritional and growth factor signaling pathways in hematopoietic stem and progenitor cells.
The enhanced metabolic activity visualized by noninvasive positron emission and computed tomographic imaging with 18 F-fluorodeoxyglucose, a glucose analog, in inflamed atherosclerotic plaques and spleen of patients with cardiovascular diseases suggests a link between hematopoietic activity and atherosclerosis. We evaluated this hypothesis by investigating the contribution of Glut1 in the hematopoietic compartment to the development of atherosclerosis in ApoE −/− mice. We found that hematopoietic Glut1 deficiency decreased atherosclerosis by preventing hematopoietic stem and progenitor cell proliferation, myelopoiesis, and the recruitment of myeloid cells in atherosclerotic lesions independent of plasma lipid profile. In ApoE −/− hematopoietic stem and progenitor cells, Glut1 serves as a key metabolic sensor for the high-energy demand of these cells for proliferation favoring glycolytic substrate utilization by mitochondria. These results provide direct evidence showing that (1) Glut1 connects the enhanced glucose uptake in atheromatous plaques and spleen of ApoE −/− mice with their myelopoiesis and (2) the activation of Glut1 in hematopoietic stem and progenitor cells of preclinical model of atherosclerosis is proatherogenic. Thus, inhibition of glucose uptake by a Glut1 inhibitor that does not cross the bloodbrain barrier may be useful in the treatment of atherosclerosis. 
Supplemental Experimental procedures
Competitive BM transplantation Competitive BM transplantation was performed as previously described. 1 In brief, CD45.1 
White blood cell counts
Leukocytes, differential blood counts, platelets, mean platelet volume (MPV), erythrocytes and hematocrit were quantified from whole blood using a hematology cell counter (Hemavet, Beckman Coulter).
Blood parameters
Plasma LDL-C, HDL-C and glucose levels were determined using commercial kits (all from Wako Diagnostics).
Histological analysis of proximal aortas
Mice were sacrificed and heart was harvested. Heart was washed with PBS then fixed with 4% paraformaldehyde. Heart was embedded in paraffin and 5µm sections of proximal aortas were performed using a Microm HM340E microtome (Microm Microtech, Francheville France) and stained with H&E as previously described. 1 Aortic lesion size of each animal was calculated as the mean of lesion areas in 6 sections from the same mouse using ImageJ software calibrated with parameters of the Leica DM5500 B (Leica Microsystemes SAS, Nanterre, France) microscope. Atherosclerotic lesions were expressed in µm2 per section.
Immunohistochemistry
Cells fixed with 4% paraformaldehyde and permeabilized with PBS containing 0.1% Triton X100 (Sigma). Unspecific staining was avoided with a blocking step in PBS 0.1% Triton X100 3% FBS. Antibodies anti F4/80, was from Cell Signaling and used as recommended by the manufacturer. Dilution for antibodies was 1/100. Slides were mounted in fluorescence mounting medium Vectamount (Vector laboratories, Inc, Burlingame, CA, USA). Pictures were taken as previously described, 1 enhanced for publication purposes and the number of positive cells were counted using ImageJ software. Count was performed 3 times per slice of tissue and the average reported.
Monocyte labeling and tracking in vivo. Classical Ly6C
hi monocytes were labeled as previously described. 2 Briefly, mononuclear cells were first transiently depleted by i.v. injection of 250µl clodronate-loaded liposomes (FormuMax, Sunnyvale, CA, USA) and 2 days later, Ly6C hi monocytes were labeled in vivo by retro-orbital i.v. injection of 1µm Fluoresbrite green fluorescent (YG) plain microspheres (Polysciences Inc.), diluted 1:4 in sterile PBS. Labeling efficiency (i.e, engulfment of latex beads) was verified in peripheral monocytes by flow cytometry 1 day after labeling and 2 days later, mice were sacrificed and the heart and aorta were perfused and isolated. Histological analysis of proximal aortas was performed as described above in a blinded manner and the mean number of latex + cells per section was determined. Nuclei were revealed with DAPI staining. Aortic arches were subjected to enzymatic digestion with a mix of collagenases I and XI (450 and 125 U/mL, respectively) and prepared for flow cytometry analysis of latex + cells per aortic arch.
Ex vivo 2-[14C]-DG uptake
In some experiments, mice were sacrificed and aortic arch and spleen were harvested and weighed. Tissues were perfused with PBS. BM cells were collected from leg bones. Splenocytes were isolated by manual disruption of the spleen through a 40-µm cell strainer with PBS. Whole aortic arch (normalized to similar tissue weight) and isolated BM cells and splenocytes were incubated with 0.1µCi 2-[ 14 C]-deoxyglucose (2-[ 14 C]-DG) in 2% BSA KrebsRinger bicarbonate buffer, pH 7.4 for 10min at 37°C, washed 3times with PBS and homogenized with 5% HClO4 solution. The radioactivity incorporated was measured and expressed as total radioactivity per tissue weight.
Splenic HSPCs and hematopoietic progenitors
Isolation of splenocytes for flow cytometry analysis was achieved as follows. Spleens were dissected from mice, perfused with PBS, and a cell suspension was obtained by manual disruption through a 40-µm cell strainer with PBS. The cellular mix was then centrifuged and subjected to a brief RBC lysis. Specific HSPC and hematopoietic progenitor subsets were identified by flow cytometry as described for BM cells.
Flow cytometry analysis of intracellular pimonidazole (Pimo)
12-week old WT and Apoe -/-mice were i.v injected with 60mg/kg Pimonidazole (Pimo; Hydpoxyprobe) 90 min before sacrifice according to the manufacturer's instructions. BM cells were stained as decribed in the 'flow cytometry analysis' section. Cells were then fixed and permeabilized with BD Perm Wash kit (BD Biosciences). Intracellular Pimo adducts were detected using an anti-Pimo FITC antibody provided in the Hydpoxyprobe Kit.
Bone marrow harvest and treatment. Primary BM cells were resuspended in IMDM (Gibco) containing 10% FCS (Stemcell) and cultured for 1h in tissue culture flasks to remove adherent cells, including macrophages. Succinate dehydrogenase (SDH) activity was determined by an ELISA kit according to the manufacturer's instructions (MitoSciences). In some experiments, mice were i.p injected with 150mg/kg 5-fluorouracil for 3 days to enrich hematopoietic stem cells in BM cultures as indicated in the figure legend. Suspended cells were then cultured for 72h in the presence of 6ng/mL IL-3 or 2ng/mL GM-CSF, Flt3L or TPO (all from R&D Systems). In some experiments, the farnesyl transferase inhibitor (FTI, Calbiochem) was used at the final concentration of 1µM, the lactate dehydrogenase inhibitor (oxamate, Sigma-Aldrich) at 50mM, the pyruvate dehydrogenase inhibitor (CPI-613, Tocris Bioscience) at 200µM, the pyruvate carboxylase inhibitor (chlorothricin, Cayman Chemical) at 100µM, the glutamate oxaloacetate transaminase inhibitor (AOA, Sigma-Aldrich) at 2mM, the mitochondrial complex I inhibitor (rotenone, Cayman Chemical) at 1µM, the succinate dehydrogenase inhibitor (3-NPA, Sigma-Aldrich) at 100µM, the acetyl-coA carboxylase inhibitor (Tofa, Sigma-Aldrich) at 10µM, tha AMPK activator (Metformin, Sigma-Aldrich) at 5mM, the IL3Rβ blocking antibody (R&D Systems) at 10µg/mL and Cyclodextrin (CD, SigmaAldrich) at 2,5mM. BM cells were also cultured in an hypoxic chamber (1% oxygen) for 6hours as indicated in the figure legend. 
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Colony-Forming Assay and in vitro 2-[14C]-DG uptake
Primary bone cells (4x10 4 ) were plated in methylcellulose-based media containing a cocktail of recombinant cytokines including SCF, IL-3 and IL-6 (Methocult, Stemcell) supplemented with 2% FCS to generate multipotential progenitor cells (CFU-GEMM) and in presence of additional GM-CSF (2ng/mL, R&Dsystems) to generate granulocyte-macrophage progenitors (CFU-GM) as previously described. 1 In some conditions, cultures were performed in 5.6mM glucose (DMEM low glucose, Gibco) rather than 25mM glucose (standard DMEM, Gibco) as described in the figure legends. After 10 days of differentiation, the number of CFUs per dish was scored or colonies were extensively washed with PBS to dissociate them from the methylcellulose-based media and were incubated with 0.1µCi 2-deoxy-[
14 C]-glucose (2-[ 14 C]-DG) in 2% BSA Krebs-Ringer bicarbonate buffer, pH 7.4 for 10min at 37°C. After 3 washes with PBS, colonies were homogenized with 5% HClO4 solution and the radioactivity incorporated into CFUs was determined by standard procedures using liquid scintillation counter.
Directed Metabolomic assays
Metabolomics analyses were performed at the Michigan core facility of the University of Michigan as previously described. 3 Briefly, Metabolites from Krebs cycle (Citrate, Succinate, Fumarate and Malate) were analyzed in WT and Apoe -/-deficient BM cells. Metabolites were extracted by exposing cells to a chilled mixture of 80% methanol, 10% chloroform, and 10% water and analyzed by LC-MS.
Respiration assays
Oxygen consumption was measured with the Oxygen Biosensor System in accordance with the manufacturer's recommendations (PreSens GmbH) and as previously described. 4 A total of 0.5 to 3x10 5 cells/well were used. In studies where Lineage marker-positive and negative (Lin + and Lin -) BM cells and Lin -Sca1 + progenitor cells were isolated for respiration analysis, magnetic lineage depletion and Sca1 enrichment (autoMACS separator, Miltenybiotec) were used. Adequate lineage depletion was confirmed by flow cytometry as previously described. 4 Oxygen consumption was determined after 2h of culture in the biosensor in presence or absence of 2µM oligomycin to inhibit mitochondrial ATP synthase.
Western blot analysis
The expression of HIF1α and LC3-II were measured in BM cell extracts by Western blot analysis as previously described. 1, 3 Primary antibodies for HIF1 α and LC3-I/II were purchased from Novus Biologicals and Cell Signaling Technology, respectively qPCRs qPCRs were performed on StepOne device from Applied Biosystem (France) using sybergreen reaction system. All the results were normalized on m36B4 gene expression. All conditions were performed in at least one experiment performed in triplicates.
Antibodies. CD45.1 (clone A20)-PE and CD45.2 (clone 104)-PercPCy5.5 were purchased from eBioscience. CD2 (RM2-5), CD3e (145-2C11), CD4 (GK1.5), CD8b (53-6.7), CD19 (eBio1D3), CD45R (B220, RA3-6B2), Gr-1 (Ly6G, RB6-8C5), Cd11b (Mac1, M1/70), Ter119 (Ly76) and NK1.1 (Ly53, PK136)-FITC were all from eBioscience and used for lineage determination. c-Kit (CD117, ACK2)-APCeFluor780 from eBioscience, Sca-1-Pacific blue from Biolegend, FcgRII/III-PE (CD16/32, 2.4G2), CD34 (RAM34)-AlexaFluor 647, CD135 (Flt3, A2F10)-PE, CD150 (Slamf1, TC15-12F12.2)-PECy7 were from Biolegend and used to quantify HSPCs and progenitor subsets. Peripheral leukocytes were stained with CD115 (AFS98)-APC, B220 or CD45R (RA3-6B2)-FITC, CD45 (30-F11)-APCCy7, Ly6C/G or Gr-1 mRNA levels (a.u) 
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